Antikörper und Tyrosinkinaseinhibitoren
Authors:
- 14 November 2010
- journal article
- leitthema
- Published by Springer Nature in Der Gynäkologe
- Vol. 43 (12) , 996-1001
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancerAnnals of Oncology, 2010
- Abstract 1780: p53 mutation predicts limited benefit from adjuvant chemotherapy in patients with localized completely resected high grade soft tissue sarcoma: a retrospective study on 117 patients of the French Sarcoma Group2010
- Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA TrialJournal of Clinical Oncology, 2009
- Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)Journal of Clinical Oncology, 2008
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 2008
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2006
- HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsOncogene, 2003
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003
- Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2British Journal of Cancer, 2000
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 1992